A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies

Journal of Translational Medicine

Meeting Report

Dirk Brockstedt¹  John Rothman²  Teresa Ramirez-Montagut²  Sarah Wallis³  John Waslif³  Andrew Cornforth⁴  Graham Pawelec⁵  Candice McCoy⁶  Pramod Srivastava⁷  Lisa H Butterfield⁸  Richard Koya⁹  Francesco Marincola^1,10  Ena Wang^1,10  Kim Margolin^1,11  Mark Ahn^1,12  Steffen Walter^1,13  Jeffrey Schlom^1,14  Adrian Bot^1,15  W Martin Kast^1,16  Marnix Bosch^1,17  Richard Harrop^1,18 

[1] Aduro Biotech, Berkeley, CA, USA;Advaxis Inc Genomics Institute of the Novartis Research Foundation, Princeton, NJ, USA;Arrowhead Publishers and Conferences, Minneapolis, MN, USA;California Stem Cell, Irvine, CA, USA;Center for Medical Research, University of Tübingen, Tübingen, Germany;Dendreon Corp, Seattle, WA, USA;Department of Immunology, University of Connecticut Health Center, Farmington, CT, USA;Department of Medicine, Surgery and Immunology, UPCI Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh, Pittsburgh, PA, USA;Department of Surgical Oncology, University of California Los Angeles, Los Angeles, CA, USA;Department of Transfusion Medicine; Infectious Disease and Immunogenetics Section, National Institutes of Health, BethesdaMD, USA;Division of Medical Oncology, University of Washington, Seattle, WA, USA;Galena Biopharma, Inc, Lake Oswego, OR, USA;Immatics Biotechnologies GmbH, Tübingen, Germany;Immunotherapeutics Group, National Institutes of Health, Bethesda, MD, USA;Kite Pharma Inc, Los Angeles, CA, USA;Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA;Northwest Biotherapeutics, Bethesda, MD, USA;Oxford BioMedica, Oxford, UK;

关键词: Cancer Stem Cell;    Initial Public Offering;    Cancer Immunotherapy;    Immune Intervention;    TRICOM;   

DOI  :  10.1186/1479-5876-10-218

 received in 2012-10-22, accepted in 2012-10-23,  发布年份 2012

来源: Springer

【 摘 要 】

While there has been significant progress in advancing novel immune therapies to the bedside, much more needs to be done to fully tap into the potential of the immune system. It has become increasingly clear that besides practical and operational challenges, the heterogeneity of cancer and the limited efficacy profile of current immunotherapy platforms are the two main hurdles. Nevertheless, the promising clinical data of several approaches point to a roadmap that carries the promise to significantly advance cancer immunotherapy. A new annual series sponsored by Arrowhead Publishers and Conferences aims at bringing together scientific and business leadership from academia and industry, to identify, share and discuss most current priorities in research and translation of novel immune interventions. This Editorial provides highlights of the first event held earlier this year and outlines the focus of the second meeting to be held in 2013 that will be dedicated to stem cells and immunotherapy.

【 授权许可】

CC BY   
© Bot et al.; licensee BioMed Central Ltd. 2012